These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20232510)

  • 1. [The health economics of attention deficit hyperactivity disorder in Germany. Part 1: Health care utilization and cost of illness].
    Schlander M; Trott GE; Schwarz O
    Nervenarzt; 2010 Mar; 81(3):289-300. PubMed ID: 20232510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct medical costs of ADHD and its comorbid conditions on basis of a claims data analysis.
    Libutzki B; Ludwig S; May M; Jacobsen RH; Reif A; Hartman CA
    Eur Psychiatry; 2019 May; 58():38-44. PubMed ID: 30802682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Who cares for patients with attention-deficit/hyperactivity disorder (ADHD)? Insights from Nordbaden (Germany) on administrative prevalence and physician involvement in health care provision.
    Schlander M; Schwarz O; Trott GE; Viapiano M; Bonauer N
    Eur Child Adolesc Psychiatry; 2007 Oct; 16(7):430-8. PubMed ID: 17468967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The health economics of attention deficit hyperactivity disorder in Germany. Part 2: Therapeutic options and their cost-effectiveness].
    Schlander M; Trott GE; Schwarz O
    Nervenarzt; 2010 Mar; 81(3):301-14. PubMed ID: 19936695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Children and adolescents with attention deficit-hyperactivity disorder: 1. Prevalence and cost of care.
    Burd L; Klug MG; Coumbe MJ; Kerbeshian J
    J Child Neurol; 2003 Aug; 18(8):555-61. PubMed ID: 13677583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Overall burden to society caused by hyperkinetic syndrome (HKS) and attention deficit hyperactivity disorder (ADHD)].
    Schöffski O; Sohn S; Happich M
    Gesundheitswesen; 2008 Jul; 70(7):398-403. PubMed ID: 18729028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Burden of Attention-Deficit/Hyperactivity Disorder among Pediatric Patients in the United States.
    Gupte-Singh K; Singh RR; Lawson KA
    Value Health; 2017 Apr; 20(4):602-609. PubMed ID: 28408002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease burden and direct medical costs of incident adult ADHD: A retrospective longitudinal analysis based on German statutory health insurance claims data.
    Libutzki B; May M; Gleitz M; Karus M; Neukirch B; Hartman CA; Reif A
    Eur Psychiatry; 2020 Oct; 63(1):e86. PubMed ID: 32998793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health care and societal costs of the management of children and adolescents with attention-deficit/hyperactivity disorder in Spain: a descriptive analysis.
    Quintero J; Ramos-Quiroga JA; Sebastián JS; Montañés F; Fernández-Jaén A; Martínez-Raga J; Giral MG; Graell M; Mardomingo MJ; Soutullo C; Eiris J; Téllez M; Pamias M; Correas J; Sabaté J; García-Orti L; Alda JA
    BMC Psychiatry; 2018 Feb; 18(1):40. PubMed ID: 29422022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns, resource use, and economic outcomes associated with atypical antipsychotic prescriptions in children and adolescents with attention-deficit hyperactivity disorder in quebec.
    Lachaine J; De G; Sikirica V; Van Stralen J; Hodgkins P; Yang H; Heroux J; Ben Amor L
    Can J Psychiatry; 2014 Nov; 59(11):597-608. PubMed ID: 25565476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Age- and Gender-specific Costs as Well as Drug Therapies of ADHD Patients].
    Klora M; Zeidler J; Lublow D; Linder R; Verheyen F; von der Schulenburg JM
    Gesundheitswesen; 2016 Jul; 78(7):e23-9. PubMed ID: 26695543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Calculation of disease-related costs in claims data analyses with the example of attention-deficit hyperactivity disorder. Comparison of methods].
    Zeidler J; Lange A; Braun S; Linder R; Engel S; Verheyen F; Graf von der Schulenburg JM
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Mar; 56(3):430-8. PubMed ID: 23455561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Descriptive comparison of drug treatment-persistent, -nonpersistent, and nondrug treatment patients with newly diagnosed attention deficit/hyperactivity disorder in Germany.
    Braun S; Russo L; Zeidler J; Linder R; Hodgkins P
    Clin Ther; 2013 May; 35(5):673-85. PubMed ID: 23587606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder.
    Guevara J; Lozano P; Wickizer T; Mell L; Gephart H
    Pediatrics; 2001 Jul; 108(1):71-8. PubMed ID: 11433056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder.
    Secnik K; Swensen A; Lage MJ
    Pharmacoeconomics; 2005; 23(1):93-102. PubMed ID: 15693731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Has the prevalence of parent-reported diagnosis of attention deficit hyperactivity disorder (ADHD) in Germany increased between 2003-2006 and 2009-2012? Results of the KiGGS-study: first follow-up (KiGGS Wave 1)].
    Schlack R; Mauz E; Hebebrand J; Hölling H;
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Jul; 57(7):820-9. PubMed ID: 24950831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Welfare consequences for people diagnosed with attention deficit hyperactivity disorder (ADHD): A matched nationwide study in Denmark.
    Jennum P; Hastrup LH; Ibsen R; Kjellberg J; Simonsen E
    Eur Neuropsychopharmacol; 2020 Aug; 37():29-38. PubMed ID: 32682821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents.
    Pelham WE; Foster EM; Robb JA
    Ambul Pediatr; 2007; 7(1 Suppl):121-31. PubMed ID: 17261491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective.
    Schein J; Adler LA; Childress A; Gagnon-Sanschagrin P; Davidson M; Kinkead F; Cloutier M; Guérin A; Lefebvre P
    J Manag Care Spec Pharm; 2022 Feb; 28(2):168-179. PubMed ID: 34806909
    [No Abstract]   [Full Text] [Related]  

  • 20. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000.
    Birnbaum HG; Kessler RC; Lowe SW; Secnik K; Greenberg PE; Leong SA; Swensen AR
    Curr Med Res Opin; 2005 Feb; 21(2):195-206. PubMed ID: 15801990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.